Regeneron Pharmaceuticals (REGN) Q3 2025 10-Q Quarterly Report
Regeneron Pharmaceuticals (REGN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Regeneron Pharmaceuticals Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $3.75B in Q3 FY2025, up slightly by $33.6M from $3.72B in Q3 FY2024
- • Net income $1.46B in Q3 FY2025 vs $1.34B Q3 FY2024; operating margin 27.3% vs 31.7% YoY (operating income $1.03B vs $1.18B)
- • Best segment: Dupixent collaboration revenue up $353.6M YoY to $1.62B in Q3; worst: EYLEA total US sales down $426M to $1.11B due to competition and pricing pressures
- • Cash/cash equivalents flat at $2.5B; Operating cash flow increased $650.5M to $3.81B in first nine months; $2.16B remain for share repurchases
- • Near-term headwinds: FDA delays and Complete Response Letters for EYLEA HD due to manufacturing inspection; ongoing competition and pricing pressure on EYLEA product line
Risk Factors
- • New risk: FDA Complete Response Letters (CRLs) for odronextamab BLA and EYLEA HD pre-filled syringe delayed approvals in 2025 due to manufacturing inspection issues
- • Most updated risk: Biosimilar competition intensifying post-EYLEA US exclusivity expiration May 2024, causing 39-41% decline in US EYLEA sales in 2025
- • Regulatory/legal risk: Ongoing US DOJ civil investigations regarding business activities may lead to penalties or enforcement actions (see Note 12)
- • Operational/market risk: Dependence on two distributors for 77% of US gross product revenue poses concentration risk affecting near-term sales distribution
- • Financial risk: Heavy reliance on collaborators Bayer and Sanofi for commercialization outside US; termination or breach could materially impair global sales and revenue
Regeneron Pharmaceuticals Q3 2025 Quarterly FinancialsXBRL
Revenue
$3.8B
▲ +0.9% YoY▲ +2.1% QoQ
Net Income
$1.5B
▲ +8.9% YoY▲ +4.9% QoQ
Net Margin
38.9%
▲ +286bp YoY▲ +103bp QoQ
Source: XBRL data from Regeneron Pharmaceuticals Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Regeneron Pharmaceuticals Quarterly Reports
Get deeper insights on Regeneron Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.